Omeros Corporation Stock News

Humanigen (NASDAQ:HGEN) and Omeros (NASDAQ:OMER) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations. Analyst Recommendations This is a breakdown of recent recommendations and price targets for Humanigen and Omeros, as []

During the last session, Omeros Corporation (NASDAQ:OMER)s traded shares were 1.46 million, with the beta value of the company hitting 0.70. At the end of the trading day, the stocks price was $7.33, reflecting an intraday gain of 3.82% or $0.27. The 52-week high for the OMER share is $23.85, that puts it down -225.38 We Just Learned Something New About Omeros Corporation (NASDAQ: OMER) This Week With Its -3.17% Loss Read More »

Investors need to pay close attention to Omeros (OMER) stock based on the movements in the options market lately.

Investors need to pay close attention to Omeros (OMER) stock based on the movements in the options market lately.

Wall Street brokerages expect Omeros Co. (NASDAQ:OMER) to announce sales of $94.43 million for the current quarter, Zacks reports. Two analysts have issued estimates for Omeros earnings, with the lowest sales estimate coming in at $31.84 million and the highest estimate coming in at $157.01 million. Omeros posted sales of $10.63 million during the same []

Morgan Stanley increased its stake in shares of Omeros Co. (NASDAQ:OMER) by 23.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 325,154 shares of the biopharmaceutical companys stock after acquiring an additional 60,823 shares during the quarter. Morgan Stanley owned []

Equities research analysts forecast that Omeros Co. (NASDAQ:OMER) will post $31.93 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Omeros earnings. The lowest sales estimate is $31.84 million and the highest is $32.01 million. Omeros reported sales of $10.63 million during the same quarter last year, []

Wall Street analysts predict that Omeros Co. (NASDAQ:OMER) will report ($0.26) earnings per share for the current quarter, Zacks reports. Two analysts have provided estimates for Omeros earnings, with the highest EPS estimate coming in at ($0.22) and the lowest estimate coming in at ($0.30). Omeros reported earnings per share of ($0.54) in the same []

Omeros' 2021 was a year to forget with the stock dropping during the year all the way from >$23 to below $6.00.

Omeros Corporation (OMER) with the stream of -6.15% also noticed, India Cemtrex, Inc. (CETX) encountered a rapid change of -7.52% in the last hour of Fridays trading session. Omeros Corporation The post Trending Stock to Observe: Omeros Corporation (NASDAQ:OMER), Cemtrex, Inc. (NASDAQ:CETX) appeared first on Stocks Equity .

The stock price of Omeros Corporation (NASDAQ: OMER) increased by over 7% during intraday trading. This is why it happened.

Omeros Corporation (NASDAQ: OMER) has agreed to sell Omidria to Rayner Surgical Group Limited for an upfront payment of $125 million with an additional $200 million in commercial milestones. Omidr

Hohimer Wealth Management LLC raised its stake in Omeros Co. (NASDAQ:OMER) by 5.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 41,580 shares of the biopharmaceutical companys stock after buying an additional 2,000 shares during the quarter. Hohimer Wealth Management LLC owned []

Omeros Corporation (NASDAQ:OMER)s traded shares stood at 0.53 million during the last session, with the companys beta value hitting 0.70. At the close of trading, the stocks price was $7.88, to imply an increase of 1.55% or $0.12 in intraday trading. The OMER shares 52-week high remains $23.85, putting it -202.66% down since that peak Omeros Corporation (NASDAQ: OMER): Can A Stock Be Down -44.84% YTD, And Still Be A Loser Read More »